AVEG 033

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined with GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) January 21, 1998
ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 36